Intrinsic Apoptosis Pathway In Neurodegeneration represents a key pathological mechanism in neurodegenerative diseases. This page explores the molecular and cellular processes involved, their contribution to disease progression, and therapeutic implications.
The intrinsic apoptosis pathway (also known as the mitochondrial apoptosis pathway) is a central mechanism of programmed cell death in neurodegenerative diseases. Unlike extrinsic apoptosis (death receptor-mediated), the intrinsic pathway is initiated by intracellular signals and is tightly regulated by the BCL-2 family of proteins.
This pathway plays a dual role in neurodegeneration: it contributes to pathological neuronal loss while also serving as a protective mechanism against malignant transformation. Understanding the balance between pro-apoptotic and anti-apoptotic signals is crucial for developing therapeutic interventions.
| Protein | Function |
|---|---|
| BAX/BAK | Pro-apoptotic effector proteins, form pores in MOM |
| BCL-2/BCL-XL/MCL-1 | Anti-apoptotic proteins, inhibit BAX/BAK |
| BIM/BID/PUMA/NOXA | BH3-only proteins, activate BAX/BAK |
| Cytochrome c | Released from mitochondria, triggers apoptosome |
| Apaf-1 | Adaptor protein, forms apoptosome with cytochrome c |
| Caspase-9 | Initiator caspase, activated by apoptosome |
| Caspase-3/7 | Effector caspases, execute cell death |
The balance between pro-survival and pro-death BCL-2 proteins determines cell fate:
Anti-apoptotic (Pro-survival):
Pro-apoptotic Effectors:
BH3-only Activators:
BH3-only Sensitizers:
| Trigger | Mechanism |
|---|---|
| DNA damage | p53 activation, PUMA/NOXA expression |
| Oxidative stress | Mitochondrial dysfunction, ROS |
| ER stress | UPR, CHOP-mediated apoptosis |
| Mitochondrial dysfunction | Loss of membrane potential |
| Excitotoxicity | Calcium overload, mitochondrial permeability |
| Aβ toxicity | Mitochondrial targeting, ROS generation |
| α-Syn toxicity | Mitochondrial impairment |
Mitochondrial outer membrane permeabilization (MOMP)
Cytochrome c release
Apoptosome formation
Caspase activation
Cellular destruction
| Approach | Target | Status |
|---|---|---|
| BCL-2 inhibitors | BCL-2, BCL-XL | Clinical trials in cancer |
| Mitochondrial protectors | VDAC, TSPO | Preclinical |
| Caspase inhibitors | Caspase-3/9 | Preclinical |
| Neurotrophic factors | BDNF, NGF | Mixed results |
In some contexts, promoting apoptosis may be therapeutic:
The study of Intrinsic Apoptosis Pathway In Neurodegeneration has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.